Unlike common nutraceuticals stocked in every health store, CJC-1295 reaches researchers through a specialist research supply market that Uihei residents reach through online vendors. What this means for Uihei researchers is that your location matters far less than your ability to verify analytical documentation — and those evaluation tools are accessible to anyone. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis showing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. The sections below cover what Uihei researchers need to know about finding, evaluating, and storing CJC-1295 for legitimate research applications.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Uihei comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Evaluating CJC-1295 vendors begins with the COA: access the batch-specific certificate before placing an order, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that omit endotoxin testing. For Uihei researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, start with a modest quantity, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Uihei
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human therapeutic use by the FDA or equivalent regulatory bodies — all information here is for educational purposes only. Proper handling of CJC-1295 requires sterile reconstitution technique — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results expressed as EU/mg or EU/mL and confirm they fall within appropriate thresholds. PubMed and bioRxiv are the primary literature resources for CJC-1295 research; favour indexed journal publications over preprints over unreviewed preprints or forum reports.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
